Title |
mTOR, a New Potential Target for Chronic Pain and Opioid-Induced Tolerance and Hyperalgesia
|
---|---|
Published in |
Molecular Pain, May 2015
|
DOI | 10.1186/s12990-015-0030-5 |
Pubmed ID | |
Authors |
Brianna Marie Lutz, Sam Nia, Ming Xiong, Yuan-Xiang Tao, Alex Bekker |
Abstract |
Chronic pain is a major public health problem with limited treatment options. Opioids remain a routine treatment for chronic pain, but extended exposure to opioid therapy can produce opioid tolerance and hyperalgesia. Although the mechanisms underlying chronic pain, opioid-induced tolerance, and opioid-induced hyperalgesia remain to be uncovered, mammalian target of rapamycin (mTOR) is involved in these disorders. The mTOR complex 1 and its triggered protein translation are required for the initiation and maintenance of chronic pain (including cancer pain) and opioid-induced tolerance/hyperalgesia. Given that mTOR inhibitors are FDA-approved drugs and an mTOR inhibitor is approved for treatment of several cancers, these findings suggest that mTOR inhibitors will likely have multiple clinical benefits, including anticancer, antinociception/anti-cancer pain, and antitolerance/hyperalgesia. This paper compares the role of mTOR complex 1 in chronic pain, opioid-induced tolerance, and opioid-induced hyperalgesia. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Unknown | 67 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 18% |
Student > Bachelor | 9 | 13% |
Student > Master | 9 | 13% |
Researcher | 8 | 12% |
Student > Doctoral Student | 5 | 7% |
Other | 7 | 10% |
Unknown | 18 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 19% |
Biochemistry, Genetics and Molecular Biology | 9 | 13% |
Agricultural and Biological Sciences | 8 | 12% |
Neuroscience | 8 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
Other | 7 | 10% |
Unknown | 18 | 26% |